Evidence map›Paper›PMID 27003828›Full record

Observational studyInternational journal of clinical pharmacy2016

Adherence with regulatory resolutions on prevention of NSAIDS-related gastrointestinal injury in Italy.

Sabrina Montagnani, Marco Tuccori, Arianna Testi, Michele Cristofano, Tiberio Corona, Stefano Salvadori, Carmelo Scarpignato, Corrado Blandizzi

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in International journal of clinical pharmacy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Sabrina MontagnaniDepartment of Clinical and Experimental Medicine, University of Pisa, Via Roma 55, 56126, Pisa, Italy. montagnani.pisa@gmail.com.
Marco TuccoriUnit of Adverse Drug Reactions Monitoring, University Hospital of Pisa, Via Roma 55, 56126, Pisa, Italy.
Arianna TestiHealth District of Pisa, Via Cocchi n.7/9, 56100, Pisa, Italy.
Michele CristofanoMedical Direction, University Hospital of Pisa, Via Cocchi n.7/9, 56100, Pisa, Italy.
Tiberio CoronaHealth District of Pisa, Via Cocchi n.7/9, 56100, Pisa, Italy.
Stefano SalvadoriInstitute of Clinical Physiology, National Research Council, Pisa, Via Moruzzi, 1, 56124, Pisa, Italy.
Carmelo ScarpignatoClinical Pharmacology and Digestive Pathophysiology Unit, Department of Clinical and Experimental Medicine, University of Parma, Via Università, 12, 43121, Parma, Italy.
Corrado BlandizziDepartment of Clinical and Experimental Medicine, University of Pisa, Via Roma 55, 56126, Pisa, Italy.
University of Pisa · ITAzienda Ospedaliera Universitaria Pisana · ITIstituto di Fisiologia Clinica · ITUniversity of Parma · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background The rate of gastrointestinal (GI) complications with non-steroidal antiinflammatory drugs (NSAIDs) or low-dose aspirin (LD-ASA) varies according to risk factors. For at risk patients, the Italian regulatory resolution enforce prophylaxis with proton pump inhibitors (PPIs) or misoprostol. Objective This study evaluated the consistency with such resolution in patients receiving NSAIDs or LD-ASA and assessed whether patients continued to receive GI protection with PPIs for an adequate time following NSAID discontinuation. Setting An observational retrospective study was conducted using data from Health District of Pisa. Methods The analysis was performed on patients receiving prescription of NSAIDs or LD-ASA, with or without concomitant PPIs or misoprostol, accordingly with the presence of risk factors (2008-2010). Prescription data were retrieved from the database of reimbursement claims for dispensed drugs, while history of past GI diseases was obtained from primary or secondary discharge diagnosis. Main outcome measure The consistency rates of PPI and misoprostol prescriptions with Italian regulatory rules in patients receiving chronic NSAIDs or LD-ASA. Results 6869 patients, receiving NSAIDs or LD-ASA during the observation period, were eligible for the analysis. For NSAIDs or LD-ASA, gastroprotection rates in patients without risk factors were: 8 and 6 % in 2008; 10 and 8 % in 2009; 9 and 6 % in 2010; while the proportions of patients with one or more risk factors not receiving gastroprotection were: 12 and 17 % in 2008; 25 and 22 % in 2009; 15 and 17 % in 2010. In patients discontinuing chronic NSAIDs, 62 % were maintained on protection with PPIs, but only 28 % continued the PPI treatment for an adequate time (60 ± 7 days). Conclusions The present analysis, although restricted to prescription patterns in a single health district, suggests scarce levels of consistency with Italian regulatory resolution on the prophylaxis of GI adverse events associated with chronic NSAIDs or LDASA.

Indexed as

Guideline AdherenceAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalAspirinDrug UtilizationFemaleGastrointestinal DiseasesHumansItalyMaleMiddle AgedMisoprostolProton Pump InhibitorsRetrospective StudiesTime FactorsAnti-Inflammatory Agents, Non-SteroidalAspirinMisoprostolProton Pump InhibitorsGastrointestinal injuryItalyMisoprostolPrescription dataProton pump inhibitors

Identifiers

PMID27003828
OpenAlexW2306028567

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.